A Randomized, Double-Blind, Placebo-Controlled, Single- And Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-986165 in Healthy Chinese Subjects
Latest Information Update: 22 Jun 2020
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Autoimmune disorders; Crohn's disease; Inflammatory bowel diseases; Liver disorders; Lupus nephritis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 25 Oct 2019 Status changed from active, no longer recruiting to completed.
- 09 Sep 2019 Planned End Date changed from 25 Jan 2020 to 28 Sep 2019.
- 09 Sep 2019 Planned primary completion date changed from 9 Sep 2019 to 28 Sep 2019.